5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | NEUTRAL | NEUTRAL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 0.98▼ | 0.97▲ | 0.97▲ | 1.33▼ | 1.60▼ |
MA10 | 0.98▼ | 0.97▲ | 0.97▲ | 1.59▼ | 1.75▼ |
MA20 | 0.97▲ | 0.97▲ | 0.97▲ | 1.68▼ | 1.60▼ |
MA50 | 0.97▲ | 1.17▼ | 1.49▼ | 1.79▼ | 1.92▼ |
MA100 | 0.97▲ | 1.52▼ | 1.69▼ | 1.59▼ | N/A |
MA200 | 1.17▼ | 1.69▼ | 1.65▼ | 1.79▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.002▲ | 0.018▲ | 0.031▲ | -0.100▼ | 0.012▲ |
RSI | 53.566▲ | 39.808▼ | 27.755▼ | 24.920▼ | 35.374▼ |
STOCH | 81.951▲ | 49.896 | 35.730 | 20.529 | 15.347▼ |
WILL %R | -32.663 | -42.077 | -51.441 | -89.302▼ | -93.814▼ |
CCI | 31.393 | 94.054 | 65.923 | -155.929▼ | -187.701▼ |
Wednesday, August 06, 2025 06:32 AM
Fractyl Health (Nasdaq:GUTS) announced new data supporting its Revita procedure and priced a new public offering.
|
Wednesday, August 06, 2025 05:41 AM
Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company pioneering pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), ...
|
Wednesday, August 06, 2025 12:30 AM
On the same day, Fractyl also reported encouraging two-year real-world clinical data on its Revita DMR treatment, developed for patients with Type 2 diabetes and related metabolic diseases. See Also: ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
08/08/25 | 0.9727 | 1.0099 | 0.94 | 0.9614 | 974,422 |
07/08/25 | 1.00 | 1.05 | 0.93 | 0.973 | 1,969,000 |
06/08/25 | 0.9899 | 1.05 | 0.825 | 1.01 | 8,786,583 |
05/08/25 | 1.88 | 1.95 | 1.84 | 1.87 | 61,448 |
04/08/25 | 1.81 | 1.92 | 1.766 | 1.86 | 110,706 |
01/08/25 | 1.84 | 1.87 | 1.76 | 1.81 | 112,200 |
31/07/25 | 1.80 | 1.94 | 1.80 | 1.84 | 112,200 |
30/07/25 | 1.92 | 1.95 | 1.80 | 1.82 | 139,800 |
29/07/25 | 1.97 | 2.00 | 1.82 | 1.82 | 195,400 |
28/07/25 | 1.95 | 2.10 | 1.9233 | 1.97 | 469,786 |
|
|
||||
|
|
||||
|
|